140 related articles for article (PubMed ID: 22103975)
1. Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.
Mancini M; Aluigi M; Leo E; Marcozzi C; Castagnetti F; Barbieri E; Santucci MA
Br J Haematol; 2012 Jan; 156(2):265-8. PubMed ID: 22103975
[No Abstract] [Full Text] [Related]
2. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Dai Y; Chen S; Venditti CA; Pei XY; Nguyen TK; Dent P; Grant S
Blood; 2008 Aug; 112(3):793-804. PubMed ID: 18505786
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
5. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
[No Abstract] [Full Text] [Related]
7. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Tanaka R; Squires MS; Kimura S; Yokota A; Nagao R; Yamauchi T; Takeuchi M; Yao H; Reule M; Smyth T; Lyons JF; Thompson NT; Ashihara E; Ottmann OG; Maekawa T
Blood; 2010 Sep; 116(12):2089-95. PubMed ID: 20548094
[TBL] [Abstract][Full Text] [Related]
8. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Young MA; Shah NP; Chao LH; Seeliger M; Milanov ZV; Biggs WH; Treiber DK; Patel HK; Zarrinkar PP; Lockhart DJ; Sawyers CL; Kuriyan J
Cancer Res; 2006 Jan; 66(2):1007-14. PubMed ID: 16424036
[TBL] [Abstract][Full Text] [Related]
9. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
11. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
12. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Kimura S
Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
[No Abstract] [Full Text] [Related]
13. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
14. Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
Mancini M; Leo E; Aluigi M; Marcozzi C; Borsi E; Barbieri E; Santucci MA
Leuk Res; 2012 Aug; 36(8):1028-34. PubMed ID: 22521726
[TBL] [Abstract][Full Text] [Related]
15. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
Kelly KR; Ecsedy J; Medina E; Mahalingam D; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS
J Cell Mol Med; 2011 Oct; 15(10):2057-70. PubMed ID: 21091633
[TBL] [Abstract][Full Text] [Related]
16. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
17. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
18. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
19. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
20. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
